Healthcare / Drug Manufacturers - GeneralShenzhen
$14.19
+0.36 (+2.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $124.7M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.0B
P/E
15.1x
↓EV/EBITDA
11.6x
↓ROE
19.9%
↑Gross Margin
61.6%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.0%
FCF CAGR
-3.9%
FCF margin
4.1%
FCF / Net income
0.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.04B · net income $631.9M · FCF $124.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.04B | $3.04B | $2.58B | $1.94B | $1.81B |
| Net Income | $631.9M | $631.9M | $507.8M | $382.9M | $273.0M |
| EBITDA | $850.8M | $850.8M | $677.7M | $519.2M | $393.0M |
| EPS | 0.91 | 0.91 | 0.73 | 0.55 | 0.45 |
| Gross Margin | 61.6% | 61.6% | 61.0% | 68.4% | 70.6% |
| Operating Margin | 26.2% | 26.2% | 24.1% | 22.5% | 19.3% |
| Net Margin | 20.8% | 20.8% | 19.7% | 19.7% | 15.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.16 | 0.08 | 0.06 |
| Current Ratio | 1.55 | 1.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $124.7M | $124.7M | $34.2M | $156.7M | $140.6M |
| Returns | |||||
| ROE | 19.9% | 19.9% | 18.3% | 14.0% | 10.1% |
| Valuation | |||||
| P/E | 15.10 | 15.10 | 20.55 | 20.29 | 23.67 |
| EV/EBITDA | 11.60 | 11.60 | 14.84 | 13.60 | 14.13 |
| P/B | 3.10 | 3.10 | 3.77 | 2.85 | 2.39 |
| Growth & Yield | |||||
| Revenue Growth | 18.0% | 18.0% | 32.7% | 7.6% | — |
| EPS Growth | 24.7% | 24.7% | 32.7% | 22.2% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
11.4%
EPS terminal req.
$1.26
Spread vs growth
13.2%
5Y implied EPS CAGR
10.9%
EPS terminal req.
$1.52
Spread vs growth
13.8%
10Y implied EPS CAGR
10.4%
EPS terminal req.
$2.45
Spread vs growth
14.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.9%
Start / end P/E
22.2x → 15.6x
EPS bridge
0.73 → 0.91
Residual
-7.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.